In a tumor mouse model, micro-patch-activated neutrophils, in combination with a checkpoint inhibitor, anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), effectively activated the immune checkpoint to suppress tumor immune evasion, resulting in complete tumor regression in one third of the treated mice 150. Here, CTLA4 is linked to neoplasm.